Psychedelics

Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.

Pharmacists must be involved in managing adverse effects and drug-drug interactions as psychedelic medicines collide with traditional psychiatric treatments.

This action is of considerable significance as it supports the regulation of cannabis and cannabis-derived products as medicine under the Federal Food, Drug and Cosmetic Act.

This is the largest known study to consider medical and recreational cannabis policies with US psychosis-related health care claims.

Lead compounds may lower the risk of abuse and other adverse effects compared with other drugs currently being evaluated for mental health disorders, such as MDMA.

Genetic variations in the 5-hydroxytryptamine serotonin receptor uniquely impacted the receptor’s response to psychedelic drugs, including LSD and psilocin, possibly explaining why patients have varied success with psychedelic treatment for psychiatric conditions.

Trials assessing psychedelic medicine were conducted in the United States for several decades before they were criminalized in 1968, with government and military funding provided for research in the field.